Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to find out the effects and the safety of an investigational
study drug called LBH589 when given to people with relapsed or refractory chronic lymphocytic
leukemia (CLL) or mantle cell lymphoma (MCL).
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute